Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H18Cl2N8.ClH |
Molecular Weight | 501.799 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CNC(=N1)C2=CN=C(NCCNC3=NC=C(C=C3)C#N)N=C2C4=CC=C(Cl)C=C4Cl
InChI
InChIKey=SCQDMKUZHIGAIB-UHFFFAOYSA-N
InChI=1S/C22H18Cl2N8.ClH/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19;/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32);1H
DescriptionSources: http://adisinsight.springer.com/drugs/800015112Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12606497
Sources: http://adisinsight.springer.com/drugs/800015112
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12606497
CHIR 99021 is a selective, pyridimidine-based, glycogen synthase kinase 3 inhibitor that is effective at low nanomolar concentrations in enzyme assays and submicromolar concentrations in isolated cells and tissues. Chiron was developing CHIR 99021 for potential use in the treatment of type 2 diabetes mellitus. CHIR 99021 promoted insulin-mediated glucose uptake and increased glucose disposal in rodent models of diabetes. However, there has been no recent development reported.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12606497 |
10.0 nM [IC50] | ||
Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12606497 |
6.7 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. | 1993 Aug 15 |
|
Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. | 2011 Nov |
|
Roles of glycogen synthase kinase 3 in Alzheimer's disease. | 2012 Sep |
|
Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. | 2015 May 29 |
|
Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling. | 2015 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12606497
In ZDF rats, a single oral dose
30 mg/kg of CHIR 99021 rapidly lowered plasma glucose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26655496
rostral (r2–3) hindbrain hindbrain neural stem cells are efficiently specified by 1.4 µM CHIR99021
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5AW8G37ZX5
Created by
admin on Sat Dec 16 16:10:28 GMT 2023 , Edited by admin on Sat Dec 16 16:10:28 GMT 2023
|
PRIMARY | |||
|
71295844
Created by
admin on Sat Dec 16 16:10:28 GMT 2023 , Edited by admin on Sat Dec 16 16:10:28 GMT 2023
|
PRIMARY | |||
|
1797989-42-4
Created by
admin on Sat Dec 16 16:10:28 GMT 2023 , Edited by admin on Sat Dec 16 16:10:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD